ClearPoint Neuro vs CytoSorbents
CytoSorbents reported revenue of $37 million in fiscal 2025, about the same as ClearPoint Neuro's $37 million in fiscal 2025. ClearPoint Neuro's revenue grew 17.8% in its latest year, and CytoSorbents' grew 4.1%. ClearPoint Neuro had an operating margin of -65.4%, against -39.8% at CytoSorbents. Free cash flow was −$24 million at ClearPoint Neuro and −$13 million at CytoSorbents.
Side by side
| ClearPoint Neuro | CytoSorbents | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $37M | $37M |
| Revenue growth | 17.8% | 4.1% |
| Revenue growth a year, last 5 years | 23.7% | −2.0% |
| Gross margin | 61.4% | 71.5% |
| Operating margin | −65.4% | −39.8% |
| Net margin | −69.1% | −22.1% |
| Free cash flow | −$24M | −$13M |
| Free cash flow margin | −66.1% | −33.8% |
| Return on capital | −104.7% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.8% | 14.3% |
| Last close | $7.31 | $5.13 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.5 million | bought $269,332, sold $0 |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ClearPoint NeuroCytoSorbents
Operating margin
Percent of revenue
ClearPoint NeuroCytoSorbents
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ClearPoint NeuroCytoSorbents
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ClearPoint Neuro and CytoSorbents pages.